en · de · es · fr · pt
creatine-notes.peptides6823.com › News › Identity And Molecular Background — Research Overview

Identity And Molecular Background — Research Overview

By Editorial Desk · published 2026-01-12 · last reviewed 2026-02-03 · News

The short version of prothymosin alpha fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-02-03. Anything still debated is marked as such rather than presented as settled.

Identity and Molecular Background

Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.

Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.

Background and Molecular Profile

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular formulaC129H215N33O55Calculated for the acetylated 28-residue peptide
AppearanceWhite to off-white powderLyophilized solid recovered from aqueous buffer
SolubilityFreely soluble in waterTypically dissolved in water or buffer before use
Typical storage-20 C or below, desiccatedProtect from light and avoid repeated freeze-thaw cycles
Identity testingReverse-phase HPLC with mass spectrometryRetention time and measured mass confirm the sequence

Storage Handling And Laboratory Analysis

Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.

Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.

Related pages on this site

Molecular Structure and Biological Background

The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.

Background from the literature

On an unknown date in 1980, the aircraft registered SSSR-86004 (constructor's number 51483200002 ["002"]) experienced a fire in engine No 4 on departure from Vnukovo on an acceptance testing flight; the crew initially shut down No. 1 in error, then No. 4, but landed safely on the reciprocal runway to the one from which they had departed, after performing a 180° turn. No casualties. The investigation into this fire resulted in a modification to the engine. In 1984, SSSR-86011 (c/n 009) was found to have suffered a tail strike on landing at Simferopol. No casualties. On March 8, 1994, RA-86119 (c/n 087) parked at Delhi airport was struck by debris of crashing Sahara India Boeing 737 (VT-SIA) flown by a trainee; both aircraft were destroyed. All 4 crew on the 737 were killed. Two Aeroflot employees and Russian ground engineer died inside the Il-86 due to a fire and an airport worker was killed on the ground. In 1998, RA-86080 (c/n 051) was found to have been overstressed, most likely by a recent heavy landing, and repairs were considered inexpedient in view of coming retirement. No casualties; aircraft broken up at Sheremetyevo Airport in 2001. On May 1, 2000, RA-86113 (c/n 081) suffered an apparent engine failure and fire on departure from Sochi. The flight crew brought the machine to a safe overweight landing. The failure and fire indications were found to have been spurious. No casualties. On August 26, 2000, RA-86066 (c/n 033) experienced a failure and fire in No 2 engine shortly after take-off from Moscow Sheremetyevo for Barcelona.

=== Arabinogalactan sidechains === The structure of the AG glycans consists of a backbone of β-1,3 linked galactose (Gal), with sidechains of β-1,6 linked Gal and have terminal residues of arabinose (Ara), rhamnose (Rha), Gal, fucose (Fuc), and glucuronic acid (GlcA). These AG glycan moieties are assembled by glycosyltransferases (GTs). O-glycosylation of AGPs is initiated by the action of Hyp-O-galactosyltransferases (Hyp-O-GalTs) that add the first Gal onto the protein. The complex glycan structures are then elaborated by a suite of glycosyltransferases, the majority of which are bio-chemically uncharacterized. The GT31 family is one of the families involved in AGP glycan backbone biosynthesis. Numerous members of the GT31 family have been identified with Hyp-O-GALT activity and the core β-(1,3)-galactan backbone is also likely to be synthesized by the GT31 family. Members of the GT14 family are implicated in adding β-(1,6)- and β-(1,3)-galactans to AGPs. In Arabidopsis, terminal sugars such as fucose are proposed to be added by AtFUT4 (a fucosyl transferase) and AtFUT6 in the GT37 family and the terminal GlcA incorporation can be catalysed by the GT14 family. A number of GTs remain to be identified, for example those responsible for terminal Rha.

== Research == At the Yale School of Medicine, Shulman has investigated the pathophysiology of insulin resistance, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2D), and related cardiometabolic conditions. His laboratory developed and applied novel 13C, 31P, and 1H NMR techniques to measure intracellular glucose, lipid, and mitochondrial metabolism in vivo. These methods allowed real-time, noninvasive assessment of metabolic fluxes in a tissue-specific manner. Early studies from his group identified defects in insulin-stimulated muscle glycogen synthesis, attributed to reduced glucose transport activity, in individuals with T2D. Later research extended these findings to individuals with prediabetes and obesity and demonstrated that exercise could bypass this defect and reverse muscle insulin resistance. Using 1H NMR, Shulman reported that intramyocellular lipid content strongly predicts muscle insulin resistance in both adults and children, and that hepatic lipid content is a strong predictor of hepatic insulin resistance in both humans and rodent models of MASLD. His team showed that lipid-induced insulin resistance in skeletal muscle stems from impaired glucose transport due to altered insulin signaling, challenging the classical Randle cycle hypothesis.

Sources: en.wikipedia.org

Further detail

There is also evidence that patients with a family history of Parkinson's or a genetic predisposition to the disease are more likely to develop the drug induced form of this disease as a result of cinnarizine treatment. In addition to antagonizing D2 receptors, treatment with cinnarizine leads to reduced presynaptic dopamine and serotonin, as well as alterations in vesicular transport of dopamine. Chronic treatment with cinnarizine builds the drug concentrations high enough that they interfere with the proton electrochemical gradient necessary for packaging dopamine into vesicles. Cinnarizine, pKa = 7.4, acts as a protonophore, which prevents the MgATP-dependent production of the electrochemical gradient crucial to the transport and storage of dopamine into vesicles, and thereby lowers the levels of dopamine in the basal ganglia neurons and leads to the Parkinson's symptoms. Several cases of pediatric and adult cinnarizine overdose have been reported, with effects including a range of symptoms such as somnolence, coma, vomiting, hypotonia, stupor, and convulsions. The cognitive complications likely result from the antihistaminic effects of cinnarizine, while the motor effects are a product of the antidopaminergic properties. In cases of overdose, the patient should be brought to and observed in a hospital for potential neurological complications.

Fiber types are established during embryonic development and are remodelled later in the adult by neural and hormonal influences. The population of satellite cells present underneath the basal lamina is necessary for the postnatal development of muscle cells.

== Structural diversity of lipids == Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Lipids may be broadly defined as hydrophobic or amphipathic small molecules that originate entirely or in part from two distinct types of biochemical subunits or "building blocks": ketoacyl and isoprene groups. The huge structural diversity found in lipids arises from the biosynthesis of various combinations of these building blocks. For example, glycerophospholipids are composed of a glycerol backbone linked to one of approximately 10 possible headgroups and also to 2 fatty acyl/alkyl chains, which in turn may have 30 or more different molecular structures. In practice, not all possible permutations are detected experimentally, due to chain preferences depending on the cell type and also to detection limits - nevertheless several hundred distinct glycerophospholipid molecular species have been detected in mammalian cells. Plant chloroplast thylakoid membranes however, have unique lipid composition as they are deficient in phospholipids. Also, their largest constituent, monogalactosyl diglyceride or MGDG, does not form aqueous bilayers. Nevertheless, dynamic studies reveal a normal lipid bilayer organisation in thylakoid membranes.

== Charlie Hebdo Speech in Cologne (2015) == On January 14, 2015, Kermani delivered a speech at the Appellhofplatz in Cologne during the memorial rally “We Are Charlie – For Freedom and Diversity.” The rally was organized by the coalition Köln stellt sich quer [Cologne puts up resistance] in memory of the victims of the Islamist-motivated terrorist attack on the editorial office of the satirical magazine Charlie Hebdo in Paris. Garnering nationwide attention, Kermani’s speech was widely discussed. It directed itselfprimarily at Muslims and the frequently repeated argument that Islam has nothing to do with terror and violence. At the same time, Kermani advocated for assigning greater importance to compassion and, first and foremost, to remaining free.

Sources: en.wikipedia.org

Supporting material

== Activities unrelated to the central dogma == The central dogma of molecular biology states that, once sequential information has passed from nucleic acid to protein, it cannot flow back from protein to nucleic acid. Some people believe that the following activities conflict with the central dogma.

The traditional kava beverage is prepared through aqueous extraction of the fresh or dried roots of the Piper methysticum plant. When using fresh roots, the outer layer is typically peeled before the root is either chewed or mechanically ground into a fine, fibrous pulp, which is then mixed with water. For dried roots, the material is finely ground, placed in a porous cloth, and infused in water. The resulting brew is usually consumed immediately after preparation, often from a communal bowl. Traditional and recreational preparation of kava beverage involves macerating, grinding, or pounding fresh or dried rhizome/root (1.0–1.5 g) and mixing it with water or coconut milk (100–150 mL) to form an emulsion, which is then agitated and strained through cloth or bark filters into a communal bowl. The resulting drink is grey and slightly pungent, with fresh rhizome/root producing a stronger and more complex beverage than dried forms due to the retention of volatile compounds. In Vanuatu, fresh root is commonly used, while in non-Pacific countries, kava is typically prepared from dried root powder soaked in water (about one tablespoon per cup) for 30 minutes before straining. On Pohnpei in Micronesia, preparation also includes mixing the kava root with the fibrous bark of Hibiscus tiliaceus before pressing.

== History == Apixaban was approved for medical use in the European Union in May 2011. A new drug application (NDA) for the approval of apixaban was submitted to the US Food and Drug Administration (FDA) by Bristol-Myers Squibb (BMS) and Pfizer jointly after the conclusion of the ARISTOTLE clinical trial in 2011. Apixaban was approved for the prevention of stroke in people with atrial fibrillation in December 2012. In March 2014, it was approved for the additional indication of preventing deep vein thrombosis and pulmonary embolism in people who have recently undergone knee or hip replacement. In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism. During its development the drug was known as BMS-562247-01. By late 2019, sales of the product by BMS accounted for thirty percent of their quarterly revenue.

== Pharmacology == The fenethylline molecule results when theophylline is covalently linked with amphetamine by an alkyl chain. Fenethylline is metabolized by the body to form two drugs, amphetamine (24.5% of oral dose) and theophylline (13.7% of oral dose), both of which are active stimulants. The physiological effects of fenethylline therefore seem to result from a combination of these two compounds, although it is not entirely clear how, and seems to involve a synergistic effect between amphetamine and theophylline produced following metabolism. The pharmacological actions of fenethylline before cleavage also remain poorly established, though it appears to act directly at several serotonin receptors.

=== Phases of growth === Potato growth can be divided into five phases. During the first phase, sprouts emerge from the seed potatoes and root growth begins. During the second, photosynthesis begins as the plant develops leaves and branches above-ground and stolons develop from lower leaf axils on the below-ground stem. In the third phase the tips of the stolons swell, forming new tubers, and the shoots continue to grow, with flowers typically developing soon after. Tuber bulking occurs during the fourth phase, when the plant begins investing the majority of its resources in its newly formed tubers. At this phase, several factors are critical to a good yield: optimal soil moisture and temperature, soil nutrient availability and balance, and resistance to pest attacks. The fifth phase is the maturation of the tubers: the leaves and stems senesce and the tuber skins harden. New tubers may start growing at the surface of the soil. Since exposure to light leads to an undesirable greening of the skins and the development of solanine as a protection from the sun's rays, growers cover surface tubers. Commercial growers cover them by piling additional soil around the base of the plant as it grows (called "hilling" up, or in British English "earthing up"). An alternative method, used by home gardeners and smaller-scale growers, involves covering the growing area with mulches such as straw or plastic sheets. At farm scale, potatoes require a well-drained neutral or mildly acidic soil (pH 6 or 7) such as a sandy loam.

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha 1?

It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.

Is thymosin alpha 1 the same as thymosin beta 4?

No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.

How is the peptide obtained for laboratory work?

Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.

How does thymosin alpha 1 differ from thymosin fraction 5?

Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.

Network